Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
26 participants
Study Classification
INTERVENTIONAL
Study Start Date
2017-05-01
Study Completion Date
2019-06-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
People with type 1 diabetes often find exercise very difficult to manage, because of the high risk for low blood glucose levels. This can occur very quickly once exercise starts and presents many risks for subjects, such as severe symptoms, confusion, passing out, seizures, and even coma or death in very severe cases. Preventing low blood glucose levels during and after exercise is important because physical exercise is a key component of managing diabetes. It is often hard to correctly adjust insulin infusion rates or doses before exercise as the relationship between exercise and changes in glucose levels in those who have type 1 diabetes is still not fully understood. Therefore, the investigators propose this study to further our understanding in this area.
This study is designed to help separate the effects of insulin from those of muscle work (non-insulin effects) on the changes in blood glucose levels during aerobic exercise. The main hypothesis is that the non-insulin effects occur quickly during exercise and account for the rapid change in blood glucose levels once aerobic exercise begins. These effects can be separated from the slower changes in insulin sensitivity that occur because of exercise, and which account for reduced insulin demand even after exercise has stopped. The investigators will investigate the effects of both moderate and intense aerobic exercise at different levels of insulin in the body to help separate the insulin and non-insulin effects.
The investigators wish to recruit 26 subjects to take part in this study. Subjects will be randomly divided into two groups, with 13 in each group. Group 1 will undergo moderate aerobic exercise, while group 2 will undergo intense aerobic exercise. Each subject will repeat the exercise study three times on three separate days at least 2 weeks apart, while having insulin infused at a low, a medium, and a high rate. Subjects will have an IV line placed in each arm, one for drawing blood relatively frequently during the study, and another for infusion of insulin, glucose, and a special glucose tracer (non-radioactive). Each study lasts about 9 hours.
Information from this study will be used to help develop a mathematical model of how glucose changes during exercise in type 1 diabetes. Such a model of type 1 diabetes and exercise will be very useful for adjusting insulin doses in patients who use multiple daily injections of insulin, and can help to guide an automated insulin delivery system, such as the artificial pancreas.
This study is designed to help separate the effects of insulin from those of muscle work (non-insulin effects) on the changes in blood glucose levels during aerobic exercise. The main hypothesis is that the non-insulin effects occur quickly during exercise and account for the rapid change in blood glucose levels once aerobic exercise begins. These effects can be separated from the slower changes in insulin sensitivity that occur because of exercise, and which account for reduced insulin demand even after exercise has stopped. The investigators will investigate the effects of both moderate and intense aerobic exercise at different levels of insulin in the body to help separate the insulin and non-insulin effects.
The investigators wish to recruit 26 subjects to take part in this study. Subjects will be randomly divided into two groups, with 13 in each group. Group 1 will undergo moderate aerobic exercise, while group 2 will undergo intense aerobic exercise. Each subject will repeat the exercise study three times on three separate days at least 2 weeks apart, while having insulin infused at a low, a medium, and a high rate. Subjects will have an IV line placed in each arm, one for drawing blood relatively frequently during the study, and another for infusion of insulin, glucose, and a special glucose tracer (non-radioactive). Each study lasts about 9 hours.
Information from this study will be used to help develop a mathematical model of how glucose changes during exercise in type 1 diabetes. Such a model of type 1 diabetes and exercise will be very useful for adjusting insulin doses in patients who use multiple daily injections of insulin, and can help to guide an automated insulin delivery system, such as the artificial pancreas.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effectiveness of Aerobic Exercise to Mitigate Hyperglycemia After Fasted Resistance Exercise
NCT05203653
Type 1 Diabetes
COMPLETED
NA
Determining the Appropriate Intensity of Exercise to Prevent Post-exercise Hypoglycemia in Persons Living With T1D
NCT03583268
Type 1 Diabetes
COMPLETED
NA
Muscle Oxygenation, Type 1 Diabetes, and Glycated Hemoglobin
NCT02051504
Type 1 Diabetes
COMPLETED
Perception of Blood Sugar Variations During Physical Activity in Healthy Subjects and Type 1 Diabetes Patients
NCT05357534
Type 1 Diabetes
UNKNOWN
NA
Effects of Frequency and Duration of Exercise in People With Type 1 Diabetes A Randomized Crossover Study
NCT04089462
Diabetes Mellitus, Type 1
Insulin Hypoglycemia
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Diabetes mellitus afflicts close to 10% of our population and 5% of those with diabetes have type 1, which is defined by an absolute deficiency of insulin. The need for managing diabetes is critical, given the economic burden of this disease, with over $175 billion dollars in direct health care costs, and almost another $70 billion in indirect costs for disability and work loss. The personal impact is equally as important for people with this disease, as diabetes mellitus is the leading cause of blindness, the need for kidney dialysis, and non-traumatic amputations in the United States. Type 2 diabetes is associated with reduced insulin sensitivity and the metabolic syndrome, and dietary modification and exercise are important components in the management of underlying insulin resistance. However, these lifestyle strategies are also important in type 1 diabetes for many reasons: 1) type 1 diabetes subjects now live into adulthood, when insulin resistance and obesity become factors for glycemic control, 2) latent autoimmune diabetes of adulthood (LADA) represents a "mixed" form of autoimmune diabetes where some type 2 diabetes characteristics such as insulin resistance can exist, and 3) dietary modification and exercise remain effective means for management of acute hyperglycemia and, in the longer term, HbA1c, potentially reducing the risk of microvascular complications. Therefore, the need for exercise is still evident in subjects with type 1 diabetes to maintain good glycemic control and to prevent complications from developing. However, exercise is challenging for people with T1D to manage. Exercise causes increased insulin sensitivity along with rapid uptake of glucose by muscle and other tissues within the body, leading to a sharp decline in glucose levels and hypoglycemia as shown by other groups as well as ours.
Without adjustments in insulin for exercise, hypoglycemia is common in persons with type 1 diabetes. In a study of 48 individuals with T1D, with no adjustments to insulin, who exercise for 60 min at a moderate intensity, glucose levels dropped on average by 40%, with 52% of subjects falling to 70 mg/dL or below. Despite this clear need for insulin adjustments for exercise, there are no uniform recommendations on how to dose insulin around the time of exercise. In 2006, the DirecNet Study Group published a study on the impact of suspending basal insulin at the start of exercise in 40 children with type 1 diabetes on insulin pump therapy. This intervention significantly reduced hypoglycemia (from 43% to 16%), but much more commonly resulted in hyperglycemia (increased from 4% to 23%). Schiavon and Cobelli et al addressed this issue of how to best adjust insulin for exercise using in silico simulations. Adjusting insulin doses in the in silico environment decreased hypoglycemia from 88% to 16% of patients when a universal adjustment was applied, and to 4% when an individual adjustment was applied.
The study described within this protocol is designed to disambiguate the impact of exercise on insulin and non-insulin mediated effects on glycemic control. To achieve this, the investigators will perform a series of stable glucose tracer studies in which subjects will be fasting for about 8 hours and will undergo aerobic exercise at a moderate and intense level for 45 minutes while insulin rates are clamped at a low (subject's basal rate), medium (basal x 1.5), and high (basal x 3) insulin infusion rate. Subject's basal rates will be obtained from injected basal insulin amounts, such as NPH/glargine/detemir, or basal rates in those who use insulin pumps and will be adjusted for the HbA1c, as described in the OHSU AP system. Di-deuterated glucose (6,6-2H2-glucose) which is not radioactive and which can be metabolized via usual pathways in the human body will be the stable tracer. Each subject per arm will undergo 3 10-hour studies while blood glucose, insulin, and glucagon levels are captured throughout the study, and catecholamine and fatty acid levels are captured during and just after the exercise period, as outlined below. Glucose tracer levels will be measured at OHSU through the Bioanalytical Shared Resource/PK core lab, and calculation of rate of appearance (Ra) and rate of disappearance (Rd) of glucose will be performed by our colleagues at McGill University using a non-steady state model of glucose dynamics.
The data obtained from this study will inform an updated model of glucose regulation in type 1 diabetes, providing exercise as an input to the model, which will be utilized in a model predictive control (MPC) system for managing type 1 diabetes. Such a system can be used to deliver insulin and/or glucagon to manage glycemic changes during and outside of exercise.
Without adjustments in insulin for exercise, hypoglycemia is common in persons with type 1 diabetes. In a study of 48 individuals with T1D, with no adjustments to insulin, who exercise for 60 min at a moderate intensity, glucose levels dropped on average by 40%, with 52% of subjects falling to 70 mg/dL or below. Despite this clear need for insulin adjustments for exercise, there are no uniform recommendations on how to dose insulin around the time of exercise. In 2006, the DirecNet Study Group published a study on the impact of suspending basal insulin at the start of exercise in 40 children with type 1 diabetes on insulin pump therapy. This intervention significantly reduced hypoglycemia (from 43% to 16%), but much more commonly resulted in hyperglycemia (increased from 4% to 23%). Schiavon and Cobelli et al addressed this issue of how to best adjust insulin for exercise using in silico simulations. Adjusting insulin doses in the in silico environment decreased hypoglycemia from 88% to 16% of patients when a universal adjustment was applied, and to 4% when an individual adjustment was applied.
The study described within this protocol is designed to disambiguate the impact of exercise on insulin and non-insulin mediated effects on glycemic control. To achieve this, the investigators will perform a series of stable glucose tracer studies in which subjects will be fasting for about 8 hours and will undergo aerobic exercise at a moderate and intense level for 45 minutes while insulin rates are clamped at a low (subject's basal rate), medium (basal x 1.5), and high (basal x 3) insulin infusion rate. Subject's basal rates will be obtained from injected basal insulin amounts, such as NPH/glargine/detemir, or basal rates in those who use insulin pumps and will be adjusted for the HbA1c, as described in the OHSU AP system. Di-deuterated glucose (6,6-2H2-glucose) which is not radioactive and which can be metabolized via usual pathways in the human body will be the stable tracer. Each subject per arm will undergo 3 10-hour studies while blood glucose, insulin, and glucagon levels are captured throughout the study, and catecholamine and fatty acid levels are captured during and just after the exercise period, as outlined below. Glucose tracer levels will be measured at OHSU through the Bioanalytical Shared Resource/PK core lab, and calculation of rate of appearance (Ra) and rate of disappearance (Rd) of glucose will be performed by our colleagues at McGill University using a non-steady state model of glucose dynamics.
The data obtained from this study will inform an updated model of glucose regulation in type 1 diabetes, providing exercise as an input to the model, which will be utilized in a model predictive control (MPC) system for managing type 1 diabetes. Such a system can be used to deliver insulin and/or glucagon to manage glycemic changes during and outside of exercise.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Type 1 Diabetes Mellitus
Hypoglycemia
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Two main arms: 1) moderate aerobic exercise, 2) intense aerobic exercise. In each arm, subjects will undergo three separate studies, i) at low insulin levels, ii) at medium insulin levels, and iii) at high insulin levels.
Primary Study Purpose
BASIC_SCIENCE
Blinding Strategy
NONE
No masking for this study.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Moderate Aerobic Exercise
Subjects will undergo moderate aerobic physical exercise (40-45% of VO2-max) on three separate days at i) low insulin levels, ii) medium insulin levels, and iii) high insulin levels.
Group Type
EXPERIMENTAL
Aerobic Exercise
Intervention Type
BEHAVIORAL
Aerobic physical exercise on treadmill, with intensity based on prior VO2-max testing during the screening visit.
Intense Aerobic Exercise
Subjects will undergo intense aerobic physical exercise (60-65% of VO2-max) on three separate days at i) low insulin levels, ii) medium insulin levels, and iii) high insulin levels.
Group Type
EXPERIMENTAL
Aerobic Exercise
Intervention Type
BEHAVIORAL
Aerobic physical exercise on treadmill, with intensity based on prior VO2-max testing during the screening visit.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Aerobic Exercise
Aerobic physical exercise on treadmill, with intensity based on prior VO2-max testing during the screening visit.
Intervention Type
BEHAVIORAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Diagnosis of type 1 diabetes mellitus for at least 1 year.
2. Male or female subjects 18 to 45 years of age.
3. Physically willing and able to perform 45 minutes of physical exercise, as determined by the investigator after reviewing the subject's activity level.
4. A hemoglobin A1c (HbA1c) less than 10%.
5. Willingness to follow all study procedures, including attending all study visits.
6. Willingness to sign informed consent and HIPAA documents.
2. Male or female subjects 18 to 45 years of age.
3. Physically willing and able to perform 45 minutes of physical exercise, as determined by the investigator after reviewing the subject's activity level.
4. A hemoglobin A1c (HbA1c) less than 10%.
5. Willingness to follow all study procedures, including attending all study visits.
6. Willingness to sign informed consent and HIPAA documents.
Exclusion Criteria
1. Female of childbearing potential who is pregnant, intending to become pregnant, breast-feeding, or is not using adequate contraceptive methods. Acceptable contraception includes birth control pill/patch/vaginal ring, Depo-Provera, Norplant, an IUD, the double barrier method (the woman uses a diaphragm and spermicide and the man uses a condom), or abstinence.
2. Any cardiovascular disease, defined as clinically significant EKG abnormality at the time of screening, or any history of: stroke, heart failure, myocardial infarction, angina pectoris, coronary arterial bypass grafting, or angioplasty. Diagnosis of 2nd or 3rd degree heart block or any non-physiological arrhythmia may be judged by the investigator to be exclusionary.
3. Renal insufficiency (GFR \< 60 ml/min, using the MDRD equation as reported by the OHSU laboratory).
4. Liver failure, cirrhosis, or any other liver disease that compromises liver function as determined by the investigator.
5. Hematocrit of less than 34%.
6. Hypertension with systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg despite treatment or who have treatment-refractory hypertension (e.g. requiring four or more medications).
7. History of severe hypoglycemia during the past 12 months prior to screening visit or hypoglycemia unawareness as judged by the investigator. Subjects will complete a hypoglycemia awareness questionnaire (included in Appendix A). Subjects will be excluded for four or more 'R' responses.
8. Adrenal insufficiency.
9. Any active infection.
10. Known of suspected abuse of alcohol, narcotics, or illicit drugs.
11. Seizure disorder.
12. Active foot ulceration.
13. Severe peripheral arterial disease characterized by ischemic rest pain or severe claudication.
14. Major surgical operation within 30 days prior to screening.
15. Use of an investigational drug within 30 days prior to screening.
16. Chronic usage of any immunosuppressive medication (such as cyclosporine, azathioprine, sirolimus, or tacrolimus).
17. Bleeding disorder, treatment with warfarin, or platelet count below 50,000.
18. Insulin resistance requiring more than 200 units per day.
19. Current administration of oral or parenteral corticosteroids.
20. Any life-threatening disease, including malignant neoplasms and medical history of malignant neoplasms within the past 5 years prior to screening (except basal cell cancer of the skin).
21. Beta blockers or non-dihydropyridine calcium channel blockers.
22. Current use of any medication intended to lower glucose other than insulin (e.g. use of liraglutide, exenatide, etc.)
23. Diagnosis of pheochromocytoma, insulinoma, or glucagonoma, personal or family history of multiple endocrine neoplasia (MEN) 2A, MEN 2B, neurofibromatosis or von Hippel-Lindau disease.
24. History of severe hypersensitivity to milk protein.
25. Conditions that may result in low levels of releasable glucose in the liver and an inadequate reversal of hypoglycemia by glucagon such as prolonged fasting, starvation or chronic hypoglycemia as determined by the investigator.
26. A positive response to any of the questions from the Physical Activity Readiness Questionnaire with one exception: subject will not be excluded if only a single blood pressure medication that doesn't impact heart rate is used, and blood pressure is controlled on the medication (blood pressure is less than 140/90 mmHg). See Appendix B.
27. Any chest discomfort with physical activity, including pain or pressure, or other types of discomfort.
28. Any clinically significant disorder which, in the opinion of the investigator, may jeopardize the subject's safety or compliance with the protocol.
2. Any cardiovascular disease, defined as clinically significant EKG abnormality at the time of screening, or any history of: stroke, heart failure, myocardial infarction, angina pectoris, coronary arterial bypass grafting, or angioplasty. Diagnosis of 2nd or 3rd degree heart block or any non-physiological arrhythmia may be judged by the investigator to be exclusionary.
3. Renal insufficiency (GFR \< 60 ml/min, using the MDRD equation as reported by the OHSU laboratory).
4. Liver failure, cirrhosis, or any other liver disease that compromises liver function as determined by the investigator.
5. Hematocrit of less than 34%.
6. Hypertension with systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg despite treatment or who have treatment-refractory hypertension (e.g. requiring four or more medications).
7. History of severe hypoglycemia during the past 12 months prior to screening visit or hypoglycemia unawareness as judged by the investigator. Subjects will complete a hypoglycemia awareness questionnaire (included in Appendix A). Subjects will be excluded for four or more 'R' responses.
8. Adrenal insufficiency.
9. Any active infection.
10. Known of suspected abuse of alcohol, narcotics, or illicit drugs.
11. Seizure disorder.
12. Active foot ulceration.
13. Severe peripheral arterial disease characterized by ischemic rest pain or severe claudication.
14. Major surgical operation within 30 days prior to screening.
15. Use of an investigational drug within 30 days prior to screening.
16. Chronic usage of any immunosuppressive medication (such as cyclosporine, azathioprine, sirolimus, or tacrolimus).
17. Bleeding disorder, treatment with warfarin, or platelet count below 50,000.
18. Insulin resistance requiring more than 200 units per day.
19. Current administration of oral or parenteral corticosteroids.
20. Any life-threatening disease, including malignant neoplasms and medical history of malignant neoplasms within the past 5 years prior to screening (except basal cell cancer of the skin).
21. Beta blockers or non-dihydropyridine calcium channel blockers.
22. Current use of any medication intended to lower glucose other than insulin (e.g. use of liraglutide, exenatide, etc.)
23. Diagnosis of pheochromocytoma, insulinoma, or glucagonoma, personal or family history of multiple endocrine neoplasia (MEN) 2A, MEN 2B, neurofibromatosis or von Hippel-Lindau disease.
24. History of severe hypersensitivity to milk protein.
25. Conditions that may result in low levels of releasable glucose in the liver and an inadequate reversal of hypoglycemia by glucagon such as prolonged fasting, starvation or chronic hypoglycemia as determined by the investigator.
26. A positive response to any of the questions from the Physical Activity Readiness Questionnaire with one exception: subject will not be excluded if only a single blood pressure medication that doesn't impact heart rate is used, and blood pressure is controlled on the medication (blood pressure is less than 140/90 mmHg). See Appendix B.
27. Any chest discomfort with physical activity, including pain or pressure, or other types of discomfort.
28. Any clinically significant disorder which, in the opinion of the investigator, may jeopardize the subject's safety or compliance with the protocol.
Minimum Eligible Age
18 Years
Maximum Eligible Age
45 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Oregon Health and Science University
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Joseph El Youssef
Assistant Professor
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Joseph El Youssef, MD
Role: PRINCIPAL_INVESTIGATOR
Oregon Health and Science University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Oregon Health & Science University
Portland, Oregon, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013 Apr;36(4):1033-46. doi: 10.2337/dc12-2625. Epub 2013 Mar 6.
Reference Type
BACKGROUND
Livingstone SJ, Levin D, Looker HC, Lindsay RS, Wild SH, Joss N, Leese G, Leslie P, McCrimmon RJ, Metcalfe W, McKnight JA, Morris AD, Pearson DW, Petrie JR, Philip S, Sattar NA, Traynor JP, Colhoun HM; Scottish Diabetes Research Network epidemiology group; Scottish Renal Registry. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010. JAMA. 2015 Jan 6;313(1):37-44. doi: 10.1001/jama.2014.16425.
Reference Type
BACKGROUND
Rusavy Z, Lacigova S. [Life expectancy of people with type 1 diabetes in the past and today]. Vnitr Lek. 2014 Sep;60(9):765-71. Czech.
Reference Type
BACKGROUND
Naik RG, Brooks-Worrell BM, Palmer JP. Latent autoimmune diabetes in adults. J Clin Endocrinol Metab. 2009 Dec;94(12):4635-44. doi: 10.1210/jc.2009-1120. Epub 2009 Oct 16.
Reference Type
BACKGROUND
Yardley JE, Hay J, Abou-Setta AM, Marks SD, McGavock J. A systematic review and meta-analysis of exercise interventions in adults with type 1 diabetes. Diabetes Res Clin Pract. 2014 Dec;106(3):393-400. doi: 10.1016/j.diabres.2014.09.038. Epub 2014 Oct 7.
Reference Type
BACKGROUND
Quirk H, Blake H, Tennyson R, Randell TL, Glazebrook C. Physical activity interventions in children and young people with Type 1 diabetes mellitus: a systematic review with meta-analysis. Diabet Med. 2014 Oct;31(10):1163-73. doi: 10.1111/dme.12531.
Reference Type
BACKGROUND
Breton MD, Brown SA, Karvetski CH, Kollar L, Topchyan KA, Anderson SM, Kovatchev BP. Adding heart rate signal to a control-to-range artificial pancreas system improves the protection against hypoglycemia during exercise in type 1 diabetes. Diabetes Technol Ther. 2014 Aug;16(8):506-11. doi: 10.1089/dia.2013.0333. Epub 2014 Apr 4.
Reference Type
BACKGROUND
Jacobs PG, Resalat N, El Youssef J, Reddy R, Branigan D, Preiser N, Condon J, Castle J. Incorporating an Exercise Detection, Grading, and Hormone Dosing Algorithm Into the Artificial Pancreas Using Accelerometry and Heart Rate. J Diabetes Sci Technol. 2015 Oct 5;9(6):1175-84. doi: 10.1177/1932296815609371.
Reference Type
BACKGROUND
Tansey MJ, Tsalikian E, Beck RW, Mauras N, Buckingham BA, Weinzimer SA, Janz KF, Kollman C, Xing D, Ruedy KJ, Steffes MW, Borland TM, Singh RJ, Tamborlane WV; Diabetes Research in Children Network (DirecNet) Study Group. The effects of aerobic exercise on glucose and counterregulatory hormone concentrations in children with type 1 diabetes. Diabetes Care. 2006 Jan;29(1):20-5. doi: 10.2337/diacare.29.1.20.
Reference Type
BACKGROUND
Diabetes Research in Children Network (DirecNet) Study Group; Tsalikian E, Kollman C, Tamborlane WB, Beck RW, Fiallo-Scharer R, Fox L, Janz KF, Ruedy KJ, Wilson D, Xing D, Weinzimer SA. Prevention of hypoglycemia during exercise in children with type 1 diabetes by suspending basal insulin. Diabetes Care. 2006 Oct;29(10):2200-4. doi: 10.2337/dc06-0495.
Reference Type
BACKGROUND
Schiavon M, Dalla Man C, Kudva YC, Basu A, Cobelli C. In silico optimization of basal insulin infusion rate during exercise: implication for artificial pancreas. J Diabetes Sci Technol. 2013 Nov 1;7(6):1461-9. doi: 10.1177/193229681300700606.
Reference Type
BACKGROUND
Jacobs PG, El Youssef J, Castle JR, Engle JM, Branigan DL, Johnson P, Massoud R, Kamath A, Ward WK. Development of a fully automated closed loop artificial pancreas control system with dual pump delivery of insulin and glucagon. Annu Int Conf IEEE Eng Med Biol Soc. 2011;2011:397-400. doi: 10.1109/IEMBS.2011.6090127.
Reference Type
BACKGROUND
Nguyen TP, Jacobs PG, Castle JR, Wilson LM, Kuehl K, Branigan D, Gabo V, Guillot F, Riddell MC, Haidar A, El Youssef J. Separating insulin-mediated and non-insulin-mediated glucose uptake during and after aerobic exercise in type 1 diabetes. Am J Physiol Endocrinol Metab. 2021 Mar 1;320(3):E425-E437. doi: 10.1152/ajpendo.00534.2020. Epub 2020 Dec 28.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
16761
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Effect of Acute Exercise on Endothelial Function in Patients With Type 1 Diabetes.
NCT01899872
UNKNOWN
NA
Physical Activity and Insulin Sensitivity Dynamics
NCT06776094
RECRUITING
NA
Effects of Resistance Exercise on Blood Glucose in Post-menopausal Women With Type 1 Diabetes
NCT05203640
RECRUITING
NA
Effect of Training Intensity on Health Outcomes in Diabetes
NCT03349944
COMPLETED
NA
Hyperglycemia, Exercise, and Endothelial Function
NCT03651713
COMPLETED
NA
High-Intensity Exercise and Endothelial Function in Type 1 Diabetes(HIIT-T1D)
NCT03451201
COMPLETED
NA
Restoring 24-hour Substrate Rhythmicity to Improve Glycemic Control by Timing of Lifestyle Factors
NCT05123963
RECRUITING
NA
Resistance Training in Type 1 Diabetes Mellitus
NCT05315037
RECRUITING
NA
Healthy Outcomes for Muscle with Exercise in T1D
NCT05740514
RECRUITING
NA
Hyperglycemia and Exercise.
NCT03284216
COMPLETED
NA
Isoenergetic High Intensity Interval Training and Moderate Intensity Training in Adults With Type I Diabetes
NCT04664205
COMPLETED
NA
An Exercise Intervention Study in Insulin-Resistant Adolescents
NCT00906724
UNKNOWN
Timing of Resistance Exercise in Type 1 Diabetes
NCT05884814
UNKNOWN
NA
Exercise Training and Endothelial Function in Type 1 Diabetes
NCT03528226
RECRUITING
NA
Fasted Exercise in People With Type 1 Diabetes
NCT03544684
COMPLETED
NA
Morning Versus Afternoon Aerobic Exercise in Type 1 Diabetes
NCT06115616
UNKNOWN
Resistance Training for the Improvement of Glycemic Control in Prediabetes
NCT06697756
ACTIVE_NOT_RECRUITING
NA
Exercise Dose-Response Effects in Prediabetes
NCT00962962
COMPLETED
NA
Comparing the Effects of Different Types of Exercise on Glucose Handling
NCT06217679
COMPLETED
NA
Fasted Exercise Training in Type 1 Diabetes (FED-T1D)
NCT06748963
RECRUITING
NA
The Effect of Brief Bodyweight Exercise on Acute Glycemic Control in Healthy Inactive Adults
NCT05144490
COMPLETED
NA
Exercise Regulation of Human Adipose Tissue
NCT03133156
COMPLETED
NA
Blood Flow Responses to an Oral Glucose Tolerance Test in Type 2 Diabetes
NCT00972452
COMPLETED
NA